Call MEDISCA now at 1-800-932-1039 1-800-932-1039

MEDISCA News at Your Fingertips

Medisca Signs Deal as Exclusive Global Distributor outside the USA & Israel for the Padagis Line of ORA Products


MONTREAL, Q.C. (January 12, 2022) – On December 9, 2021, Medisca entered into an exclusive global manufacture, supply, license and distribution agreement with Padagis (formerly, the Rx Division of Perrigo) for their ORA Product Line consisting of the following Padagis products in finished form ORA-Plus®, ORA-Sweet®, ORA-Sweet® SF, ORA-Blend®, and ORA-Blend® SF.

MEDISCA Launches New Thyroid API - Now Available to Compounding Pharmacists after Years of Industry-wide Disruptions to Supply.


PLATTSBURGH, N.Y. (August 26, 2021) - MEDISCA has officially begun accepting orders for its long-awaited thyroid active pharmaceutical ingredient (thyroid API), creating a consistent supply for compounding pharmacists, prescribers and of course, their patients.

MEDISCA and fellow industry leaders lobby for revisions to compounded expiry dates and succeed


Over the last several months, MEDISCA Australia along with other industry leaders have been actively putting forward to the Australian Pharmaceutical Formulary & Handbook (APF), scientific rationale for longer expiry dates for compounded preparations. Medisca is now pleased to see the efforts of the compounding community come to fruition.

MEDISCA $100,000 pledge to protect compounded hormone therapy encourages industry-wide response - doubling donations in 1 month.


Earlier this year MEDISCA announced that in June it would match up to $100,000 in donations to the Alliance for Pharmacy Compounding (APC) Media Fund Campaign, encouraging investments to support APC’s nationwide marketing and lobbying effort to secure compounded hormone therapy. The result was astonishing, bringing in $113,545 in investments from compounding pharmacies, which, with Medisca’s match, elevated the final amount raised in June to $213,545.

MEDISCA strategic partnership stabilizes industry supply of thyroid API


MEDISCA has finalized an exclusive distribution agreement with pharmaceutical manufacturer Sichuan Deebio Pharmaceutical Co.,Ltd to provide thyroid active pharmaceutical ingredient (API) to the compounding and non-compounding industries in the United States. This agreement will bring much-needed stability to a market that has seen inconsistent supply for several years.

MEDISCA Pledges $100,000 to Alliance for Pharmacy Compounding (APC) National Media Campaign to Help Protect Compounded Hormone Therapy Medications


MEDISCA Pledges $100,000 to Alliance for Pharmacy Compounding (APC) National Media Campaign to Help Protect Compounded Hormone Therapy Medications.




We have placed cookies on your device to help make this website better.

We also use cookies to collect information for making reports and to help us improve the site. The cookies collect information in an anonymous form.

Copyright® 1989-2022 Medisca Inc.
All rights reserved

Drug Distributor